Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel Free XYL Stock Alerts

Xylem (XYL) Financials

Xylem logo
$108.70 +3.01 (+2.85%)
Closing price 03:59 PM Eastern
Extended Trading
$110.00 +1.30 (+1.20%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Xylem

Annual Income Statements for Xylem

This table shows Xylem's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 340 260 331 549 401 254 427 355 609 890 957
Consolidated Net Income / (Loss)		 340 260 330 549 401 254 427 355 609 890 950
Net Income / (Loss) Continuing Operations		 340 260 330 549 401 254 427 355 609 890 950
Total Pre-Tax Income 		403 340 466 585 416 285 511 440 635 1,087 1,181
Total Operating Income		 449 408 552 654 486 367 585 622 652 1,009 1,223
Total Gross Profit		 1,404 1,462 1,847 2,026 2,046 1,830 1,975 2,084 2,717 3,212 3,475
Total Revenue		 3,653 3,771 4,707 5,207 5,249 4,876 5,195 5,522 7,364 8,562 9,035
Operating Revenue		 3,653 3,771 4,707 5,207 5,249 4,876 5,195 5,522 7,364 8,562 9,035
Total Cost of Revenue		 2,249 2,309 2,860 3,181 3,203 3,046 3,220 3,438 4,647 5,350 5,560
Operating Cost of Revenue		 2,249 2,309 2,860 3,181 3,203 3,046 3,220 3,438 4,647 5,350 5,560
Total Operating Expenses		 955 1,054 1,295 1,372 1,560 1,463 1,390 1,462 2,065 2,203 2,252
Selling, General & Admin Expense		 854 914 1,089 1,161 1,158 1,143 1,179 1,227 1,757 1,911 1,923
Research & Development Expense		 95 110 181 189 191 187 204 206 232 230 226
Impairment Charge		 - - 0.00 22 211 133 7.00 29 76 62 103
Other Special Charges / (Income)		 - - - - - 0.00 0.00 - 0.00 0.00 0.00
Total Other Income / (Expense), net		 -46 -68 -86 -69 -70 -82 -74 -182 -17 78 -42
Interest Expense		 55 70 82 82 67 77 76 50 49 44 29
Interest & Investment Income		 - - - - - - - 0.00 0.00 152 0.00
Other Income / (Expense), net		 9.00 2.00 -4.00 13 -3.00 -5.00 2.00 -132 32 -30 -13
Income Tax Expense		 63 80 136 36 15 31 84 85 26 197 231
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 0.00 -1.00 - - - - - 0.00 0.00 -7.00
Basic Earnings per Share		 $1.88 $1.45 $1.84 $3.05 $2.23 $1.41 $2.37 $1.97 $2.81 $3.67 $3.93
Weighted Average Basic Shares Outstanding		 180.89M 179.11M 179.60M 179.78M 179.99M 180.12M 180.25M 180.22M 217.01M 242.58M 243.37M
Diluted Earnings per Share		 $1.87 $1.45 $1.83 $3.03 $2.21 $1.40 $2.35 $1.96 $2.79 $3.65 $3.92
Weighted Average Diluted Shares Outstanding		 181.74M 180.04M 180.90M 181.13M 181.20M 181.10M 181.53M 180.98M 218.18M 243.52M 243.99M
Weighted Average Basic & Diluted Shares Outstanding		 180.90M 179.30M 179.90M 180M 180.22M 180.36M 179.90M 180.28M 241.77M 243.05M 243.14M
Cash Dividends to Common per Share		 $0.56 $0.62 $0.72 $0.84 $0.96 $1.04 $1.12 $1.20 $1.32 $1.44 $1.60

Quarterly Income Statements for Xylem

This table shows Xylem's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 266 153 194 217 326 169 226 227 335 193 263
Consolidated Net Income / (Loss)		 266 153 194 217 326 167 224 226 333 189 261
Net Income / (Loss) Continuing Operations		 266 153 194 217 326 167 224 226 333 189 261
Total Pre-Tax Income 		210 196 247 269 375 217 299 297 368 244 364
Total Operating Income		 211 209 253 280 267 231 305 334 353 244 390
Total Gross Profit		 756 752 819 784 857 768 892 883 932 803 963
Total Revenue		 2,118 2,033 2,169 2,104 2,256 2,069 2,301 2,268 2,397 2,125 2,336
Operating Revenue		 2,118 2,033 2,169 2,104 2,256 2,069 2,301 2,268 2,397 2,125 2,336
Total Cost of Revenue		 1,362 1,281 1,350 1,320 1,399 1,301 1,409 1,385 1,465 1,322 1,373
Operating Cost of Revenue		 1,362 1,281 1,350 1,320 1,399 1,301 1,409 1,385 1,465 1,322 1,373
Total Operating Expenses		 545 543 566 504 590 537 587 549 579 559 573
Selling, General & Admin Expense		 466 474 485 445 507 460 503 474 486 472 503
Research & Development Expense		 60 59 58 55 58 56 58 52 60 56 59
Impairment Charge		 19 10 23 4.00 25 21 26 23 33 31 11
Total Other Income / (Expense), net		 -1.00 -13 -6.00 -11 108 -14 -6.00 -37 15 0.00 -26
Interest Expense		 14 14 11 10 9.00 8.00 9.00 6.00 6.00 4.00 7.00
Other Income / (Expense), net		 13 1.00 5.00 -1.00 -35 -6.00 3.00 -31 21 4.00 -19
Income Tax Expense		 -56 43 53 52 49 50 75 71 35 55 103
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 0.00 0.00 - -2.00 -2.00 -1.00 -2.00 -4.00 -2.00
Basic Earnings per Share		 $1.18 $0.63 $0.80 $0.89 $1.35 $0.69 $0.93 $0.93 $1.38 $0.79 $1.11
Weighted Average Basic Shares Outstanding		 217.01M 241.85M 242.57M 242.93M 242.58M 243.11M 243.40M 243.45M 243.37M 242.77M 236.30M
Diluted Earnings per Share		 $1.17 $0.63 $0.80 $0.89 $1.33 $0.69 $0.93 $0.93 $1.37 $0.79 $1.11
Weighted Average Diluted Shares Outstanding		 218.18M 243.02M 243.54M 243.75M 243.52M 243.78M 243.86M 244.09M 243.99M 243.36M 236.57M
Weighted Average Basic & Diluted Shares Outstanding		 241.77M 242.45M 242.89M 242.94M 243.05M 243.35M 243.41M 243.47M 243.14M 237.69M 233.49M

Annual Cash Flow Statements for Xylem

This table details how cash moves in and out of Xylem's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 17 -372 106 -118 428 1,151 -526 -405 75 102 358
Net Cash From Operating Activities		 464 497 686 586 839 824 538 596 837 1,263 1,241
Net Cash From Continuing Operating Activities		 464 497 686 586 839 824 538 596 837 1,263 1,241
Net Income / (Loss) Continuing Operations		 340 260 330 549 401 254 427 355 609 890 950
Consolidated Net Income / (Loss)		 340 260 330 549 401 254 427 355 609 890 950
Depreciation Expense		 88 87 109 117 117 117 118 111 193 258 267
Amortization Expense		 45 64 125 144 140 134 127 125 243 304 308
Non-Cash Adjustments To Reconcile Net Income		 -1.00 27 42 20 229 178 17 182 112 -9.00 166
Changes in Operating Assets and Liabilities, net		 -8.00 59 80 -244 -48 141 -151 -177 -320 -180 -450
Net Cash From Investing Activities		 -132 -1,886 -181 -643 -231 -169 -183 -191 -628 -482 -471
Net Cash From Continuing Investing Activities		 -132 -1,886 -181 -643 -231 -169 -183 -191 -628 -482 -471
Purchase of Property, Plant & Equipment		 -117 -124 -170 -237 -226 -183 -208 -208 -271 -321 -331
Acquisitions		 -18 -1,782 -33 -433 -18 - -5.00 -3.00 -476 -193 -200
Purchase of Investments		 0.00 0.00 -11 -11 -7.00 -200 0.00 -21 -58 -17 -49
Sale of Property, Plant & Equipment		 0.00 1.00 1.00 - - - 3.00 4.00 1.00 4.00 17
Divestitures		 1.00 0.00 16 22 0.00 0.00 10 1.00 105 11 49
Sale and/or Maturity of Investments		 0.00 0.00 10 11 20 212 14 33 29 35 43
Other Investing Activities, net		 2.00 19 6.00 5.00 0.00 2.00 3.00 3.00 42 -1.00 0.00
Net Cash From Financing Activities		 -262 1,034 -421 -40 -177 473 -855 -790 -157 -615 -501
Net Cash From Continuing Financing Activities		 -262 1,034 -421 -40 -177 473 -855 -790 -157 -615 -501
Repayment of Debt		 -4.00 -688 -282 -172 -257 -642 -603 -529 -173 -313 -116
Repurchase of Common Equity		 -179 -4.00 -25 -59 -40 -61 -68 -52 -25 -20 -15
Payment of Dividends		 -102 -112 -130 -152 -174 -188 -203 -217 -299 -350 -391
Issuance of Debt		 0.00 1,814 0.00 336 281 1,344 0.00 0.00 278 1.00 1.00
Other Financing Activities, net		 23 24 16 7.00 13 20 19 8.00 62 67 20
Effect of Exchange Rate Changes		 -53 -17 22 -21 -3.00 23 -26 -20 23 -53 90
Other Net Changes in Cash		 - - - - - - - - 0.00 -11 -1.00
Cash Interest Paid		 52 49 78 78 77 77 99 76 69 67 61
Cash Income Taxes Paid		 75 78 57 75 107 41 83 91 211 219 267

Quarterly Cash Flow Statements for Xylem

This table details how cash moves in and out of Xylem's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 314 -72 -132 174 132 80 111 21 288 -463 747
Net Cash From Operating Activities		 455 89 288 311 575 33 305 360 543 108 290
Net Cash From Continuing Operating Activities		 455 89 288 311 575 200 305 360 543 301 553
Net Income / (Loss) Continuing Operations		 266 153 194 217 326 336 226 222 333 382 524
Consolidated Net Income / (Loss)		 266 153 194 217 326 336 226 222 333 382 524
Depreciation Expense		 61 61 62 68 67 68 69 64 66 65 65
Amortization Expense		 76 73 83 73 75 77 76 78 77 75 75
Non-Cash Adjustments To Reconcile Net Income		 30 31 33 18 -91 54 34 69 9.00 32 20
Changes in Operating Assets and Liabilities, net		 22 -229 -84 -65 198 -335 -100 -73 58 -253 -131
Net Cash From Investing Activities		 -89 -51 -77 -65 -289 -15 -125 -189 -142 -76 -22
Net Cash From Continuing Investing Activities		 -89 -51 -77 -65 -289 -15 -125 -189 -142 -76 -22
Purchase of Property, Plant & Equipment		 -94 -74 -73 -74 -100 -71 -98 -79 -83 -90 -89
Acquisitions		 1.00 0.00 - -2.00 -190 -7.00 -39 -108 -45 -1.00 -5.00
Sale of Property, Plant & Equipment		 -1.00 1.00 2.00 - 1.00 5.00 - 10 2.00 1.00 10
Divestitures		 2.00 11 - - - 48 2.00 -2.00 1.00 0.00 59
Sale and/or Maturity of Investments		 3.00 13 5.00 12 5.00 12 9.00 15 7.00 14 3.00
Net Cash From Financing Activities		 -86 -82 -337 -101 -95 -116 -128 -138 -119 -683 199
Net Cash From Continuing Financing Activities		 -86 -82 -337 -101 -95 -116 -128 -138 -119 -683 199
Repayment of Debt		 -10 -12 -277 -15 -9.00 -12 -35 -40 -29 -14 -12
Repurchase of Common Equity		 -15 -15 -3.00 -1.00 -1.00 -13 - -1.00 -1.00 -563 -680
Payment of Dividends		 -80 -88 -87 -88 -87 -98 -98 -97 -98 -106 -101
Issuance of Debt		 2.00 0.00 - - 1.00 1.00 3.00 -3.00 - 0.00 990
Other Financing Activities, net		 17 33 30 3.00 1.00 6.00 2.00 3.00 9.00 0.00 2.00
Other Net Changes in Cash		 - 0.00 - - - 11 - -11 -1.00 -5.00 17
Cash Interest Paid		 26 13 23 13 18 12 20 11 18 11 18
Cash Income Taxes Paid		 52 39 71 50 59 37 138 33 59 28 129

Annual Balance Sheets for Xylem

This table presents Xylem's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 4,657 6,474 6,860 7,222 7,710 8,750 8,276 7,952 16,112 16,493 17,634
Total Current Assets		 2,005 1,839 2,071 2,094 2,450 3,523 3,160 3,012 3,884 4,098 4,641
Cash & Equivalents		 680 308 414 296 724 1,875 1,349 944 1,019 1,121 1,479
Accounts Receivable		 749 843 956 1,031 1,036 923 953 1,096 1,617 1,668 1,759
Inventories, net		 433 522 524 595 539 558 700 799 1,018 996 983
Prepaid Expenses		 143 166 177 172 151 167 158 173 230 236 244
Other Current Nonoperating Assets		 - - - - - - - - 0.00 77 176
Plant, Property, & Equipment, net		 439 616 643 656 658 657 644 630 1,169 1,152 1,159
Total Noncurrent Assets		 2,213 4,019 4,146 4,472 4,602 4,570 4,472 4,310 11,059 11,243 11,834
Goodwill		 1,584 2,632 2,768 2,976 2,839 2,854 2,792 2,719 7,587 7,980 8,332
Intangible Assets		 435 1,201 1,168 1,232 1,174 1,093 1,016 930 2,529 2,379 2,272
Other Noncurrent Operating Assets		 194 186 210 264 589 623 664 661 943 884 1,230
Total Liabilities & Shareholders' Equity		 4,657 6,474 6,860 7,222 7,710 8,750 8,276 7,952 16,112 16,493 17,634
Total Liabilities		 2,573 4,267 4,341 4,440 4,743 5,774 5,050 4,449 5,936 5,611 5,885
Total Current Liabilities		 823 1,238 1,100 1,389 1,501 1,956 1,391 1,590 2,205 2,336 2,856
Short-Term Debt		 78 260 0.00 257 276 600 - 0.00 16 38 534
Accounts Payable		 338 457 549 586 597 569 639 723 968 1,006 1,013
Accrued Expenses		 407 521 551 546 628 787 752 867 1,221 1,271 1,237
Other Current Nonoperating Liabilities		 - - - - - - - - 0.00 21 72
Total Noncurrent Liabilities		 1,750 3,029 3,241 3,051 3,242 3,818 3,659 2,859 3,731 3,275 3,029
Long-Term Debt		 1,196 2,108 2,200 2,051 2,040 2,484 2,440 1,880 2,268 1,978 1,408
Noncurrent Deferred & Payable Income Tax Liabilities		 118 352 252 303 310 242 287 222 557 497 405
Noncurrent Employee Benefit Liabilities		 335 408 442 400 445 519 438 286 344 304 317
Other Noncurrent Operating Liabilities		 101 161 347 297 447 573 494 471 562 496 899
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - - - - - 0.00 235 258
Total Equity & Noncontrolling Interests		 2,084 2,207 2,519 2,782 2,967 2,976 3,226 3,503 10,176 10,647 11,491
Total Preferred & Common Equity		 2,084 2,190 2,503 2,768 2,957 2,968 3,218 3,494 10,166 10,642 11,480
Total Common Equity		 2,084 2,190 2,503 2,768 2,957 2,968 3,218 3,494 10,166 10,642 11,480
Common Stock		 1,836 1,878 1,914 1,952 1,993 2,039 2,091 2,136 8,567 8,690 8,762
Retained Earnings		 885 1,033 1,227 1,639 1,866 1,930 2,154 2,292 2,601 3,140 3,706
Treasury Stock		 -399 -403 -428 -487 -527 -588 -656 -708 -733 -753 -768
Accumulated Other Comprehensive Income / (Loss)		 -238 -318 -210 -336 -375 -413 -371 -226 -269 -435 -220
Noncontrolling Interest		 0.00 17 16 14 10 8.00 8.00 9.00 10 5.00 11

Quarterly Balance Sheets for Xylem

This table presents Xylem's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 15,905 16,112 15,924 15,765 16,046 16,493 16,559 17,191 17,295 16,954 17,342
Total Current Assets		 3,651 3,884 3,893 3,781 4,013 4,098 4,084 4,369 4,441 4,030 4,394
Cash & Equivalents		 705 1,019 947 815 989 1,121 1,059 1,170 1,191 808 1,276
Accounts Receivable		 1,653 1,617 1,641 1,675 1,707 1,668 1,743 1,837 1,803 1,796 1,875
Inventories, net		 1,080 1,018 1,039 1,057 1,091 996 1,022 1,071 1,035 991 1,016
Prepaid Expenses		 213 230 266 234 226 236 260 283 254 243 219
Other Current Nonoperating Assets		 - 0.00 - - - 77 0.00 8.00 158 192 8.00
Plant, Property, & Equipment, net		 1,132 1,169 1,141 1,144 1,158 1,152 1,157 1,189 1,141 1,151 1,167
Total Noncurrent Assets		 11,122 11,059 10,890 10,840 10,875 11,243 11,318 11,633 11,713 11,773 11,781
Goodwill		 7,149 7,587 7,509 7,509 7,593 7,980 8,061 8,237 8,280 8,292 8,256
Intangible Assets		 3,039 2,529 2,454 2,374 2,326 2,379 2,332 2,354 2,319 2,213 2,150
Other Noncurrent Operating Assets		 934 943 927 957 956 884 925 1,042 1,114 1,268 1,375
Total Liabilities & Shareholders' Equity		 15,905 16,112 15,924 15,765 16,046 16,493 16,559 17,191 17,295 16,954 17,342
Total Liabilities		 5,964 5,936 5,721 5,417 5,446 5,611 5,505 5,882 5,850 5,725 6,676
Total Current Liabilities		 2,120 2,205 2,331 2,042 2,052 2,336 2,166 2,301 2,269 2,755 2,724
Short-Term Debt		 17 16 285 17 17 38 41 68 49 531 531
Accounts Payable		 943 968 948 940 930 1,006 958 1,047 968 969 1,013
Accrued Expenses		 1,160 1,221 1,098 1,085 1,105 1,271 1,167 1,186 1,172 1,182 1,180
Other Current Nonoperating Liabilities		 - 0.00 - - - 21 0.00 0.00 80 73 0.00
Total Noncurrent Liabilities		 3,844 3,731 3,390 3,375 3,394 3,275 3,339 3,581 3,581 2,970 3,952
Long-Term Debt		 2,253 2,268 1,985 1,981 1,977 1,978 1,974 1,928 1,913 1,407 2,395
Noncurrent Deferred & Payable Income Tax Liabilities		 724 557 558 552 535 497 486 427 492 437 446
Noncurrent Employee Benefit Liabilities		 281 344 323 325 332 304 317 340 323 308 301
Other Noncurrent Operating Liabilities		 586 562 524 517 550 496 562 886 853 818 810
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - 0.00 - - - 235 232 228 226 249 242
Total Equity & Noncontrolling Interests		 9,941 10,176 10,203 10,348 10,600 10,647 10,822 11,081 11,219 10,980 10,424
Total Preferred & Common Equity		 9,930 10,166 10,195 10,341 10,593 10,642 10,816 11,074 11,207 10,972 10,421
Total Common Equity		 9,930 10,166 10,195 10,341 10,593 10,642 10,816 11,074 11,207 10,972 10,421
Common Stock		 8,532 8,567 8,621 8,663 8,676 8,690 8,708 8,723 8,738 8,775 8,790
Retained Earnings		 2,416 2,601 2,667 2,774 2,902 3,140 3,211 3,339 3,469 3,794 3,956
Treasury Stock		 -718 -733 -748 -751 -753 -753 -766 -766 -767 -1,368 -2,023
Accumulated Other Comprehensive Income / (Loss)		 -300 -269 -345 -345 -232 -435 -337 -222 -233 -229 -302
Noncontrolling Interest		 11 10 8.00 7.00 7.00 5.00 6.00 7.00 12 8.00 3.00

Annual Metrics And Ratios for Xylem

This table displays calculated financial ratios and metrics derived from Xylem's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -6.72% 3.23% 24.82% 10.62% 0.81% -7.11% 6.54% 6.29% 33.36% 16.27% 5.52%
EBITDA Growth		 -4.21% -5.08% 39.39% 18.67% -20.26% -17.16% 35.73% -12.74% 54.27% 37.59% 15.83%
EBIT Growth		 -3.58% -10.48% 33.66% 21.72% -27.59% -25.05% 62.15% -16.52% 39.59% 43.13% 23.60%
NOPAT Growth		 2.21% -17.64% 25.29% 57.01% -23.67% -30.18% 49.45% 2.66% 24.60% 32.12% 19.08%
Net Income Growth		 0.89% -23.53% 26.92% 66.36% -26.96% -36.66% 68.11% -16.86% 71.55% 46.14% 6.74%
EPS Growth		 2.19% -22.46% 26.21% 65.57% -27.06% -36.65% 67.86% -16.60% 42.35% 30.82% 7.40%
Operating Cash Flow Growth		 11.54% 7.11% 38.03% -14.58% 43.17% -1.79% -34.71% 10.78% 40.44% 50.90% -1.74%
Free Cash Flow Firm Growth		 -21.48% -384.53% 127.64% -64.65% 463.89% -0.34% -49.10% 6.45% -1,778.78% 108.56% 9.27%
Invested Capital Growth		 -2.55% 59.34% 0.89% 11.36% -4.90% -8.20% 3.15% 2.83% 157.74% 2.45% 3.30%
Revenue Q/Q Growth		 -1.30% 2.75% 4.02% 2.14% -0.29% 0.04% -0.95% 3.43% 9.06% 1.64% 1.59%
EBITDA Q/Q Growth		 -0.51% -1.58% 8.31% 4.50% -0.80% -2.70% -4.91% 9.67% 9.70% 0.85% 8.71%
EBIT Q/Q Growth		 0.22% -7.24% 10.93% 5.37% -1.02% -3.72% -6.38% 14.75% 3.32% 0.82% 13.30%
NOPAT Q/Q Growth		 5.83% -17.08% 6.90% 34.50% -20.71% 16.28% -7.93% 4.97% 22.31% -3.70% 9.00%
Net Income Q/Q Growth		 5.59% -19.75% 6.45% 39.34% -21.06% 13.39% -7.58% 11.29% 23.78% 7.23% 0.74%
EPS Q/Q Growth		 6.86% -19.44% 6.40% 38.99% -21.07% 13.82% -7.84% 11.36% 14.34% 4.58% 1.03%
Operating Cash Flow Q/Q Growth		 9.69% 3.97% 13.95% -15.68% 29.28% -2.14% -21.80% 31.28% 12.50% 10.50% -2.51%
Free Cash Flow Firm Q/Q Growth		 -19.13% -518.30% 126.35% -31.20% 23.24% 1.12% -40.02% -0.32% 3.32% -28.04% 61.50%
Invested Capital Q/Q Growth		 -1.07% 53.60% -3.97% 0.76% -4.58% -4.15% 0.35% 0.91% -0.56% 1.00% -0.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 38.43% 38.77% 39.24% 38.91% 38.98% 37.53% 38.02% 37.74% 36.90% 37.51% 38.46%
EBITDA Margin		 16.18% 14.88% 16.61% 17.82% 14.10% 12.57% 16.02% 13.15% 15.21% 18.00% 19.76%
Operating Margin		 12.29% 10.82% 11.73% 12.56% 9.26% 7.53% 11.26% 11.26% 8.85% 11.78% 13.54%
EBIT Margin		 12.54% 10.87% 11.64% 12.81% 9.20% 7.42% 11.30% 8.87% 9.29% 11.43% 13.39%
Profit (Net Income) Margin		 9.31% 6.89% 7.01% 10.54% 7.64% 5.21% 8.22% 6.43% 8.27% 10.39% 10.51%
Tax Burden Percent		 84.37% 76.47% 70.82% 93.85% 96.39% 89.12% 83.56% 80.68% 95.91% 81.88% 80.44%
Interest Burden Percent		 87.99% 82.93% 85.04% 87.71% 86.13% 78.73% 87.05% 89.80% 92.84% 111.03% 97.60%
Effective Tax Rate		 15.63% 23.53% 29.18% 6.15% 3.61% 10.88% 16.44% 19.32% 4.09% 18.12% 19.56%
Return on Invested Capital (ROIC)		 13.96% 8.98% 9.12% 13.49% 10.02% 7.48% 11.50% 11.46% 7.88% 7.13% 8.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 7.57% 5.07% 5.95% 10.08% 6.27% 2.26% 6.12% -3.03% 6.39% 13.20% 2.62%
Return on Net Nonoperating Assets (RNNOA)		 2.19% 3.13% 4.84% 7.22% 3.93% 1.07% 2.27% -0.91% 1.03% 1.32% 0.14%
Return on Equity (ROE)		 16.15% 12.12% 13.97% 20.71% 13.95% 8.55% 13.77% 10.55% 8.90% 8.45% 8.40%
Cash Return on Invested Capital (CROIC)		 16.54% -36.77% 8.23% 2.74% 15.04% 16.04% 8.39% 8.68% -80.31% 4.72% 5.01%
Operating Return on Assets (OROA)		 9.65% 7.37% 8.22% 9.47% 6.47% 4.40% 6.90% 6.04% 5.68% 6.01% 7.09%
Return on Assets (ROA)		 7.17% 4.67% 4.95% 7.80% 5.37% 3.09% 5.02% 4.38% 5.06% 5.46% 5.57%
Return on Common Equity (ROCE)		 16.15% 12.07% 13.87% 20.60% 13.89% 8.52% 13.73% 10.52% 8.89% 8.35% 8.21%
Return on Equity Simple (ROE_SIMPLE)		 16.31% 11.87% 13.18% 19.83% 13.56% 8.56% 13.27% 10.16% 5.99% 8.36% 0.00%
Net Operating Profit after Tax (NOPAT)		 379 312 391 614 468 327 489 502 625 826 984
NOPAT Margin		 10.37% 8.27% 8.30% 11.79% 8.93% 6.71% 9.41% 9.09% 8.49% 9.65% 10.89%
Net Nonoperating Expense Percent (NNEP)		 6.39% 3.92% 3.17% 3.41% 3.74% 5.22% 5.38% 14.49% 1.48% -6.07% 5.64%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 9.32% 5.02% 6.52% 7.32%
Cost of Revenue to Revenue		 61.57% 61.23% 60.76% 61.09% 61.02% 62.47% 61.98% 62.26% 63.10% 62.49% 61.54%
SG&A Expenses to Revenue		 23.38% 24.24% 23.14% 22.30% 22.06% 23.44% 22.69% 22.22% 23.86% 22.32% 21.28%
R&D to Revenue		 2.60% 2.92% 3.85% 3.63% 3.64% 3.84% 3.93% 3.73% 3.15% 2.69% 2.50%
Operating Expenses to Revenue		 26.14% 27.95% 27.51% 26.35% 29.72% 30.00% 26.76% 26.48% 28.04% 25.73% 24.93%
Earnings before Interest and Taxes (EBIT)		 458 410 548 667 483 362 587 490 684 979 1,210
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 591 561 782 928 740 613 832 726 1,120 1,541 1,785
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.83 3.70 4.52 4.05 4.55 5.93 6.51 5.55 2.67 2.64 2.88
Price to Tangible Book Value (P/TBV)		 90.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 543.69 99.29 37.72
Price to Revenue (P/Rev)		 1.61 2.15 2.41 2.15 2.56 3.61 4.03 3.51 3.69 3.28 3.66
Price to Earnings (P/E)		 17.33 31.19 34.21 20.43 33.52 69.34 49.08 54.64 44.64 31.57 34.53
Dividend Yield		 1.71% 1.37% 1.14% 1.35% 1.29% 1.06% 0.96% 1.12% 1.17% 1.25% 1.18%
Earnings Yield		 5.77% 3.21% 2.92% 4.89% 2.98% 1.44% 2.04% 1.83% 2.24% 3.17% 2.90%
Enterprise Value to Invested Capital (EV/IC)		 2.42 2.39 3.05 2.76 3.30 4.50 5.11 4.58 2.49 2.49 2.79
Enterprise Value to Revenue (EV/Rev)		 1.78 2.70 2.79 2.54 2.87 3.86 4.25 3.68 3.86 3.41 3.74
Enterprise Value to EBITDA (EV/EBITDA)		 10.98 18.16 16.79 14.27 20.33 30.71 26.51 28.02 25.41 18.97 18.92
Enterprise Value to EBIT (EV/EBIT)		 14.16 24.84 23.95 19.86 31.15 52.01 37.57 41.51 41.61 29.86 27.91
Enterprise Value to NOPAT (EV/NOPAT)		 17.12 32.65 33.58 21.58 32.11 57.56 45.12 40.53 45.51 35.39 34.33
Enterprise Value to Operating Cash Flow (EV/OCF)		 13.98 20.49 19.14 22.60 17.93 22.85 41.00 34.13 34.00 23.15 27.22
Enterprise Value to Free Cash Flow (EV/FCFF)		 14.45 0.00 37.20 106.16 21.39 26.86 61.81 53.55 0.00 53.53 56.60
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.61 1.07 0.87 0.83 0.78 1.04 0.76 0.54 0.22 0.19 0.17
Long-Term Debt to Equity		 0.57 0.96 0.87 0.74 0.69 0.83 0.76 0.54 0.22 0.18 0.12
Financial Leverage		 0.29 0.62 0.81 0.72 0.63 0.47 0.37 0.30 0.16 0.10 0.05
Leverage Ratio		 2.25 2.59 2.82 2.66 2.60 2.77 2.75 2.41 1.76 1.55 1.51
Compound Leverage Factor		 1.98 2.15 2.40 2.33 2.24 2.18 2.39 2.17 1.63 1.72 1.47
Debt to Total Capital		 37.94% 51.76% 46.62% 45.34% 43.84% 50.89% 43.06% 34.92% 18.33% 15.63% 14.18%
Short-Term Debt to Total Capital		 2.32% 5.68% 0.00% 5.05% 5.22% 9.90% 0.00% 0.00% 0.13% 0.29% 3.90%
Long-Term Debt to Total Capital		 35.62% 46.08% 46.62% 40.29% 38.61% 40.99% 43.06% 34.92% 18.20% 15.34% 10.28%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.37% 0.34% 0.28% 0.19% 0.13% 0.14% 0.17% 0.08% 1.86% 1.96%
Common Equity to Total Capital		 62.06% 47.87% 53.04% 54.38% 55.97% 48.98% 56.79% 64.91% 81.59% 82.51% 83.85%
Debt to EBITDA		 2.16 4.22 2.81 2.49 3.13 5.03 2.93 2.59 2.04 1.31 1.09
Net Debt to EBITDA		 1.01 3.67 2.28 2.17 2.15 1.97 1.31 1.29 1.13 0.58 0.26
Long-Term Debt to EBITDA		 2.02 3.76 2.81 2.21 2.76 4.05 2.93 2.59 2.03 1.28 0.79
Debt to NOPAT		 3.36 7.59 5.63 3.76 4.94 9.43 4.99 3.75 3.65 2.44 1.97
Net Debt to NOPAT		 1.57 6.60 4.57 3.28 3.40 3.70 2.23 1.87 2.02 1.08 0.47
Long-Term Debt to NOPAT		 3.16 6.76 5.63 3.34 4.35 7.59 4.99 3.75 3.63 2.39 1.43
Altman Z-Score		 3.05 2.27 2.94 2.98 3.07 3.05 3.97 4.13 3.70 4.11 4.52
Noncontrolling Interest Sharing Ratio		 0.00% 0.40% 0.70% 0.57% 0.42% 0.30% 0.26% 0.25% 0.14% 1.19% 2.25%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.44 1.49 1.88 1.51 1.63 1.80 2.27 1.89 1.76 1.75 1.63
Quick Ratio		 1.74 0.93 1.25 0.96 1.17 1.43 1.65 1.28 1.20 1.19 1.13
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 449 -1,277 353 125 703 701 357 380 -6,377 546 597
Operating Cash Flow to CapEx		 396.58% 404.07% 405.92% 247.26% 371.24% 450.27% 262.44% 292.16% 310.00% 398.42% 395.22%
Free Cash Flow to Firm to Interest Expense		 8.16 -18.24 4.30 1.52 10.50 9.10 4.70 7.60 -130.14 12.41 20.58
Operating Cash Flow to Interest Expense		 8.44 7.10 8.37 7.15 12.52 10.70 7.08 11.92 17.08 28.70 42.79
Operating Cash Flow Less CapEx to Interest Expense		 6.31 5.34 6.30 4.26 9.15 8.32 4.38 7.84 11.57 21.50 31.97
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.77 0.68 0.71 0.74 0.70 0.59 0.61 0.68 0.61 0.53 0.53
Accounts Receivable Turnover		 4.81 4.74 5.23 5.24 5.08 4.98 5.54 5.39 5.43 5.21 5.27
Inventory Turnover		 4.89 4.84 5.47 5.69 5.65 5.55 5.12 4.59 5.12 5.31 5.62
Fixed Asset Turnover		 8.12 7.15 7.48 8.02 7.99 7.42 7.99 8.67 8.19 7.38 7.82
Accounts Payable Turnover		 6.65 5.81 5.69 5.61 5.42 5.22 5.33 5.05 5.50 5.42 5.51
Days Sales Outstanding (DSO)		 75.94 77.05 69.75 69.64 71.87 73.32 65.90 67.72 67.24 70.02 69.22
Days Inventory Outstanding (DIO)		 74.57 75.48 66.75 64.20 64.61 65.73 71.30 79.57 71.36 68.70 64.96
Days Payable Outstanding (DPO)		 54.86 62.84 64.19 65.12 67.40 69.86 68.47 72.30 66.41 67.34 66.27
Cash Conversion Cycle (CCC)		 95.66 89.69 72.30 68.72 69.07 69.19 68.74 74.99 72.18 71.38 67.91
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2,678 4,267 4,305 4,794 4,559 4,185 4,317 4,439 11,441 11,721 12,108
Invested Capital Turnover		 1.35 1.09 1.10 1.14 1.12 1.12 1.22 1.26 0.93 0.74 0.76
Increase / (Decrease) in Invested Capital		 -70 1,589 38 489 -235 -374 132 122 7,002 280 387
Enterprise Value (EV)		 6,486 10,186 13,127 13,244 15,044 18,828 22,056 20,341 28,459 29,234 33,776
Market Capitalization		 5,892 8,109 11,325 11,218 13,442 17,611 20,957 19,396 27,184 28,099 33,044
Book Value per Share		 $11.62 $12.21 $13.94 $15.40 $16.42 $16.47 $17.85 $19.39 $42.17 $43.80 $47.15
Tangible Book Value per Share		 $0.36 ($9.16) ($7.98) ($8.01) ($5.86) ($5.43) ($3.27) ($0.86) $0.21 $1.16 $3.60
Total Capital		 3,358 4,575 4,719 5,090 5,283 6,060 5,666 5,383 12,460 12,898 13,691
Total Debt		 1,274 2,368 2,200 2,308 2,316 3,084 2,440 1,880 2,284 2,016 1,942
Total Long-Term Debt		 1,196 2,108 2,200 2,051 2,040 2,484 2,440 1,880 2,268 1,978 1,408
Net Debt		 594 2,060 1,786 2,012 1,592 1,209 1,091 936 1,265 895 463
Capital Expenditures (CapEx)		 117 123 169 237 226 183 205 204 270 317 314
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 580 553 557 666 501 292 420 478 676 679 840
Debt-free Net Working Capital (DFNWC)		 1,260 861 971 962 1,225 2,167 1,769 1,422 1,695 1,800 2,319
Net Working Capital (NWC)		 1,182 601 971 705 949 1,567 1,769 1,422 1,679 1,762 1,785
Net Nonoperating Expense (NNE)		 39 52 61 65 67 73 62 147 16 -64 34
Net Nonoperating Obligations (NNO)		 594 2,060 1,786 2,012 1,592 1,209 1,091 936 1,265 839 359
Total Depreciation and Amortization (D&A)		 133 151 234 261 257 251 245 236 436 562 575
Debt-free, Cash-free Net Working Capital to Revenue		 15.88% 14.66% 11.83% 12.79% 9.54% 5.99% 8.08% 8.66% 9.18% 7.93% 9.30%
Debt-free Net Working Capital to Revenue		 34.49% 22.83% 20.63% 18.48% 23.34% 44.44% 34.05% 25.75% 23.02% 21.02% 25.67%
Net Working Capital to Revenue		 32.36% 15.94% 20.63% 13.54% 18.08% 32.14% 34.05% 25.75% 22.80% 20.58% 19.76%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.88 $1.45 $1.84 $3.05 $2.23 $1.41 $2.37 $1.97 $2.81 $3.67 $3.93
Adjusted Weighted Average Basic Shares Outstanding		 180.89M 179.11M 179.63M 179.78M 180M 180.12M 180.25M 180.22M 217.01M 242.58M 243.37M
Adjusted Diluted Earnings per Share		 $1.87 $1.45 $1.83 $3.03 $2.21 $1.40 $2.35 $1.96 $2.79 $3.65 $3.92
Adjusted Weighted Average Diluted Shares Outstanding		 181.74M 180.04M 180.86M 181.13M 181.20M 181.10M 181.53M 180.98M 218.18M 243.52M 243.99M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 178.49M 179.47M 179.89M 179.55M 180.22M 180.36M 179.90M 180.28M 241.77M 243.05M 243.14M
Normalized Net Operating Profit after Tax (NOPAT)		 384 335 409 634 672 446 495 525 698 877 1,067
Normalized NOPAT Margin		 10.51% 8.88% 8.68% 12.18% 12.80% 9.14% 9.52% 9.51% 9.48% 10.24% 11.81%
Pre Tax Income Margin		 11.03% 9.02% 9.90% 11.23% 7.93% 5.85% 9.84% 7.97% 8.62% 12.70% 13.07%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 8.33 5.86 6.68 8.13 7.21 4.70 7.72 9.80 13.96 22.25 41.72
NOPAT to Interest Expense		 6.89 4.46 4.77 7.48 6.99 4.25 6.43 10.04 12.76 18.78 33.92
EBIT Less CapEx to Interest Expense		 6.20 4.10 4.62 5.24 3.84 2.32 5.03 5.72 8.45 15.05 30.90
NOPAT Less CapEx to Interest Expense		 4.76 2.70 2.71 4.59 3.62 1.87 3.73 5.96 7.25 11.57 23.10
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 30.00% 43.08% 39.39% 27.69% 43.39% 74.02% 47.54% 61.13% 49.10% 39.33% 41.16%
Augmented Payout Ratio		 82.65% 44.62% 46.97% 38.43% 53.37% 98.03% 63.47% 75.77% 53.20% 41.57% 42.74%

Quarterly Metrics And Ratios for Xylem

This table displays calculated financial ratios and metrics derived from Xylem's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 243,141,405.00 237,693,493.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 243,141,405.00 237,693,493.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.79 1.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 40.64% 40.40% 25.96% 1.35% 6.52% 1.77% 6.09% 7.79% 6.25% 2.71% 1.52%
EBITDA Growth		 37.79% 76.41% 84.86% 21.39% 3.60% 7.56% 12.41% 5.95% 38.24% 4.86% 12.80%
EBIT Growth		 10.89% 55.56% 104.76% 40.20% 3.57% 7.14% 19.38% 8.60% 61.21% 10.22% 20.45%
NOPAT Growth		 72.09% 58.51% 106.92% 43.93% -13.15% 8.97% 14.99% 12.52% 37.62% 6.31% 22.38%
Net Income Growth		 78.52% 54.55% 110.87% 42.76% 22.56% 9.15% 15.46% 4.15% 2.15% 13.17% 16.52%
EPS Growth		 42.68% 16.67% 77.78% 41.27% 13.68% 9.52% 16.25% 4.49% 3.01% 14.49% 19.35%
Operating Cash Flow Growth		 25.69% 568.42% 928.57% -16.62% 26.37% -62.92% 5.90% 15.76% -5.57% 227.27% -4.92%
Free Cash Flow Firm Growth		 -20,320.25% -83,278.70% 105.29% 101.83% 99.29% 95.45% -197.56% -319.78% -41.11% 86.61% 126.84%
Invested Capital Growth		 157.74% 148.78% -1.52% 0.86% 2.45% 4.20% 5.17% 4.59% 3.30% 1.92% 1.49%
Revenue Q/Q Growth		 2.02% -4.01% 6.69% -3.00% 7.22% -8.29% 11.21% -1.43% 5.69% -11.35% 9.93%
EBITDA Q/Q Growth		 4.34% -4.71% 17.15% 4.22% -10.95% -1.07% 22.43% -1.77% 16.18% -24.95% 31.70%
EBIT Q/Q Growth		 12.56% -6.25% 22.86% 8.14% -16.85% -3.02% 36.89% -1.62% 23.43% -33.69% 49.60%
NOPAT Q/Q Growth		 70.31% -38.96% 21.80% 13.67% 2.76% -23.41% 28.53% 11.23% 25.68% -40.83% 47.96%
Net Income Q/Q Growth		 75.00% -42.48% 26.80% 11.86% 50.23% -48.77% 34.13% 0.89% 47.35% -43.24% 38.10%
EPS Q/Q Growth		 85.71% -46.15% 26.98% 11.25% 49.44% -48.12% 34.78% 0.00% 47.31% -42.34% 40.51%
Operating Cash Flow Q/Q Growth		 21.98% -80.44% 223.60% 7.99% 84.89% -94.26% 824.24% 18.03% 50.83% -80.11% 168.52%
Free Cash Flow Firm Q/Q Growth		 3.10% 0.07% 105.60% -66.32% -137.74% -539.46% -20.01% 24.12% 75.77% 39.33% 340.59%
Invested Capital Q/Q Growth		 -0.56% 0.74% 0.04% 0.64% 1.00% 2.47% 0.97% 0.09% -0.25% 1.09% 0.56%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 35.69% 36.99% 37.76% 37.26% 37.99% 37.12% 38.77% 38.93% 38.88% 37.79% 41.22%
EBITDA Margin		 17.04% 16.92% 18.58% 19.96% 16.58% 17.88% 19.69% 19.62% 21.57% 18.26% 21.88%
Operating Margin		 9.96% 10.28% 11.66% 13.31% 11.84% 11.16% 13.26% 14.73% 14.73% 11.48% 16.70%
EBIT Margin		 10.58% 10.33% 11.89% 13.26% 10.28% 10.87% 13.39% 13.36% 15.60% 11.67% 15.88%
Profit (Net Income) Margin		 12.56% 7.53% 8.94% 10.31% 14.45% 8.07% 9.73% 9.96% 13.89% 8.89% 11.17%
Tax Burden Percent		 126.67% 78.06% 78.54% 80.67% 86.93% 76.96% 74.92% 76.09% 90.49% 77.46% 71.70%
Interest Burden Percent		 93.75% 93.33% 95.74% 96.42% 161.64% 96.44% 97.08% 98.02% 98.40% 98.39% 98.11%
Effective Tax Rate		 -26.67% 21.94% 21.46% 19.33% 13.07% 23.04% 25.08% 23.91% 9.51% 22.54% 28.30%
Return on Invested Capital (ROIC)		 11.70% 7.90% 6.62% 7.83% 7.61% 6.28% 7.33% 8.40% 10.11% 6.67% 8.94%
ROIC Less NNEP Spread (ROIC-NNEP)		 11.59% 7.04% 6.30% 7.14% 16.53% 5.33% 6.88% 5.08% 12.37% 6.67% 7.43%
Return on Net Nonoperating Assets (RNNOA)		 1.86% 1.21% 0.93% 0.89% 1.65% 0.57% 0.64% 0.39% 0.65% 0.59% 0.83%
Return on Equity (ROE)		 13.57% 9.10% 7.55% 8.72% 9.26% 6.85% 7.96% 8.79% 10.76% 7.26% 9.77%
Cash Return on Invested Capital (CROIC)		 -80.31% -76.82% 8.32% 6.57% 4.72% 3.04% 2.33% 3.11% 5.01% 6.31% 7.09%
Operating Return on Assets (OROA)		 6.47% 6.88% 6.27% 6.99% 5.40% 5.76% 7.09% 7.13% 8.26% 6.33% 8.39%
Return on Assets (ROA)		 7.69% 5.01% 4.71% 5.44% 7.59% 4.27% 5.16% 5.32% 7.36% 4.83% 5.91%
Return on Common Equity (ROCE)		 13.55% 9.09% 7.54% 8.71% 9.15% 6.77% 7.88% 8.69% 10.52% 7.10% 9.56%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 6.50% 7.40% 7.84% 0.00% 8.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 267 163 199 226 232 178 228 254 319 189 280
NOPAT Margin		 12.62% 8.03% 9.16% 10.74% 10.29% 8.59% 9.93% 11.21% 13.33% 8.89% 11.97%
Net Nonoperating Expense Percent (NNEP)		 0.12% 0.86% 0.32% 0.69% -8.92% 0.95% 0.45% 3.32% -2.27% 0.00% 1.52%
Return On Investment Capital (ROIC_SIMPLE)		 2.15% - - - 1.83% 1.38% 1.75% 1.93% 2.38% 1.46% 2.09%
Cost of Revenue to Revenue		 64.31% 63.01% 62.24% 62.74% 62.01% 62.88% 61.23% 61.07% 61.12% 62.21% 58.78%
SG&A Expenses to Revenue		 22.00% 23.32% 22.36% 21.15% 22.47% 22.23% 21.86% 20.90% 20.28% 22.21% 21.53%
R&D to Revenue		 2.83% 2.90% 2.67% 2.61% 2.57% 2.71% 2.52% 2.29% 2.50% 2.64% 2.53%
Operating Expenses to Revenue		 25.73% 26.71% 26.10% 23.95% 26.15% 25.95% 25.51% 24.21% 24.16% 26.31% 24.53%
Earnings before Interest and Taxes (EBIT)		 224 210 258 279 232 225 308 303 374 248 371
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 361 344 403 420 374 370 453 445 517 388 511
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.67 3.05 3.18 3.10 2.64 2.68 2.84 3.20 2.88 2.65 2.70
Price to Tangible Book Value (P/TBV)		 543.69 133.95 71.80 48.66 99.29 68.64 65.18 59.05 37.72 62.22 1,873.18
Price to Revenue (P/Rev)		 3.69 3.91 3.92 3.89 3.28 3.38 3.61 4.04 3.66 3.20 3.08
Price to Earnings (P/E)		 44.64 46.87 42.98 39.52 31.57 32.05 33.56 37.87 34.53 29.62 27.60
Dividend Yield		 1.17% 1.05% 1.02% 1.04% 1.25% 1.24% 1.18% 1.06% 1.18% 1.36% 1.40%
Earnings Yield		 2.24% 2.13% 2.33% 2.53% 3.17% 3.12% 2.98% 2.64% 2.90% 3.38% 3.62%
Enterprise Value to Invested Capital (EV/IC)		 2.49 2.81 2.95 2.91 2.49 2.52 2.68 3.04 2.79 2.49 2.44
Enterprise Value to Revenue (EV/Rev)		 3.86 4.08 4.06 4.01 3.41 3.52 3.73 4.15 3.74 3.35 3.29
Enterprise Value to EBITDA (EV/EBITDA)		 25.41 25.54 23.43 22.13 18.97 19.29 20.12 22.48 18.92 16.88 16.12
Enterprise Value to EBIT (EV/EBIT)		 41.61 42.70 38.24 34.82 29.86 30.41 31.17 34.56 27.91 24.69 23.14
Enterprise Value to NOPAT (EV/NOPAT)		 45.51 47.20 43.20 39.41 35.39 35.94 37.32 40.90 34.33 30.61 28.65
Enterprise Value to Operating Cash Flow (EV/OCF)		 34.00 34.29 28.28 29.58 23.15 25.04 26.59 29.00 27.22 23.13 23.05
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 35.25 44.55 53.53 84.63 117.90 99.89 56.60 39.82 34.63
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.22 0.22 0.19 0.19 0.19 0.18 0.18 0.17 0.17 0.17 0.27
Long-Term Debt to Equity		 0.22 0.19 0.19 0.19 0.18 0.18 0.17 0.17 0.12 0.13 0.22
Financial Leverage		 0.16 0.17 0.15 0.13 0.10 0.11 0.09 0.08 0.05 0.09 0.11
Leverage Ratio		 1.76 1.73 1.57 1.56 1.55 1.53 1.52 1.51 1.51 1.50 1.57
Compound Leverage Factor		 1.65 1.61 1.51 1.50 2.50 1.47 1.48 1.48 1.48 1.48 1.54
Debt to Total Capital		 18.33% 18.20% 16.18% 15.83% 15.63% 15.42% 15.00% 14.63% 14.18% 14.72% 21.53%
Short-Term Debt to Total Capital		 0.13% 2.28% 0.14% 0.14% 0.29% 0.31% 0.51% 0.37% 3.90% 4.03% 3.91%
Long-Term Debt to Total Capital		 18.20% 15.91% 16.05% 15.70% 15.34% 15.10% 14.49% 14.27% 10.28% 10.69% 17.62%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.08% 0.06% 0.06% 0.06% 1.86% 1.82% 1.77% 1.78% 1.96% 1.95% 1.80%
Common Equity to Total Capital		 81.59% 81.74% 83.76% 84.11% 82.51% 82.76% 83.23% 83.59% 83.85% 83.33% 76.67%
Debt to EBITDA		 2.04 1.79 1.37 1.31 1.31 1.29 1.23 1.19 1.09 1.07 1.57
Net Debt to EBITDA		 1.13 1.04 0.81 0.66 0.58 0.61 0.51 0.47 0.26 0.63 0.89
Long-Term Debt to EBITDA		 2.03 1.56 1.36 1.29 1.28 1.26 1.19 1.17 0.79 0.78 1.29
Debt to NOPAT		 3.65 3.31 2.53 2.32 2.44 2.40 2.29 2.17 1.97 1.95 2.79
Net Debt to NOPAT		 2.02 1.93 1.50 1.17 1.08 1.14 0.95 0.85 0.47 1.14 1.58
Long-Term Debt to NOPAT		 3.63 2.89 2.51 2.30 2.39 2.35 2.21 2.12 1.43 1.41 2.29
Altman Z-Score		 3.60 4.15 4.61 4.60 3.97 4.14 4.19 4.69 4.37 4.03 3.56
Noncontrolling Interest Sharing Ratio		 0.14% 0.14% 0.09% 0.09% 1.19% 1.16% 1.12% 1.11% 2.25% 2.22% 2.18%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.76 1.67 1.85 1.96 1.75 1.89 1.90 1.96 1.63 1.46 1.61
Quick Ratio		 1.20 1.11 1.22 1.31 1.19 1.29 1.31 1.32 1.13 0.95 1.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6,735 -6,730 377 127 -48 -306 -368 -279 -68 -41 99
Operating Cash Flow to CapEx		 478.95% 121.92% 405.63% 420.27% 580.81% 50.00% 311.22% 521.74% 670.37% 121.35% 367.09%
Free Cash Flow to Firm to Interest Expense		 -481.05 -480.70 34.25 12.69 -5.32 -38.28 -40.83 -46.47 -11.26 -10.25 14.09
Operating Cash Flow to Interest Expense		 32.50 6.36 26.18 31.10 63.89 4.13 33.89 60.00 90.50 27.00 41.43
Operating Cash Flow Less CapEx to Interest Expense		 25.71 1.14 19.73 23.70 52.89 -4.13 23.00 48.50 77.00 4.75 30.14
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.61 0.67 0.53 0.53 0.53 0.53 0.53 0.53 0.53 0.54 0.53
Accounts Receivable Turnover		 5.43 5.75 5.04 5.01 5.21 5.08 4.97 5.07 5.27 5.14 4.92
Inventory Turnover		 5.12 5.30 4.82 4.89 5.31 5.21 5.10 5.17 5.62 5.55 5.31
Fixed Asset Turnover		 8.19 8.97 7.34 7.36 7.38 7.48 7.48 7.74 7.82 7.88 7.75
Accounts Payable Turnover		 5.50 6.06 5.56 5.67 5.42 5.63 5.46 5.79 5.51 5.79 5.38
Days Sales Outstanding (DSO)		 67.24 63.46 72.47 72.79 70.02 71.83 73.42 72.02 69.22 71.04 74.23
Days Inventory Outstanding (DIO)		 71.36 68.85 75.68 74.57 68.70 70.04 71.53 70.62 64.96 65.83 68.69
Days Payable Outstanding (DPO)		 66.41 60.20 65.64 64.34 67.34 64.78 66.79 63.05 66.27 63.01 67.80
Cash Conversion Cycle (CCC)		 72.18 72.10 82.51 83.03 71.38 77.10 78.16 79.60 67.91 73.86 75.12
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11,441 11,526 11,531 11,605 11,721 12,010 12,127 12,138 12,108 12,240 12,308
Invested Capital Turnover		 0.93 0.98 0.72 0.73 0.74 0.73 0.74 0.75 0.76 0.75 0.75
Increase / (Decrease) in Invested Capital		 7,002 6,893 -178 99 280 484 596 533 387 230 181
Enterprise Value (EV)		 28,459 32,407 34,073 33,810 29,234 30,228 32,541 36,912 33,776 30,442 29,993
Market Capitalization		 27,184 31,076 32,883 32,798 28,099 29,034 31,480 35,903 33,044 29,055 28,098
Book Value per Share		 $42.17 $42.15 $42.65 $43.61 $43.80 $44.50 $45.51 $46.04 $47.15 $45.13 $43.84
Tangible Book Value per Share		 $0.21 $0.96 $1.89 $2.77 $1.16 $1.74 $1.98 $2.50 $3.60 $1.92 $0.06
Total Capital		 12,460 12,473 12,346 12,594 12,898 13,069 13,305 13,407 13,691 13,167 13,592
Total Debt		 2,284 2,270 1,998 1,994 2,016 2,015 1,996 1,962 1,942 1,938 2,926
Total Long-Term Debt		 2,268 1,985 1,981 1,977 1,978 1,974 1,928 1,913 1,408 1,407 2,395
Net Debt		 1,265 1,323 1,183 1,005 895 956 826 771 463 1,130 1,650
Capital Expenditures (CapEx)		 95 73 71 74 99 66 98 69 81 89 79
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 676 900 941 989 679 900 966 1,030 840 998 925
Debt-free Net Working Capital (DFNWC)		 1,695 1,847 1,756 1,978 1,800 1,959 2,136 2,221 2,319 1,806 2,201
Net Working Capital (NWC)		 1,679 1,562 1,739 1,961 1,762 1,918 2,068 2,172 1,785 1,275 1,670
Net Nonoperating Expense (NNE)		 1.27 10 4.71 8.87 -94 11 4.49 28 -14 0.00 19
Net Nonoperating Obligations (NNO)		 1,265 1,323 1,183 1,005 839 956 818 693 359 1,011 1,642
Total Depreciation and Amortization (D&A)		 137 134 145 141 142 145 145 142 143 140 140
Debt-free, Cash-free Net Working Capital to Revenue		 9.18% 11.32% 11.21% 11.74% 7.93% 10.47% 11.07% 11.58% 9.30% 10.98% 10.14%
Debt-free Net Working Capital to Revenue		 23.02% 23.24% 20.91% 23.48% 21.02% 22.78% 24.47% 24.97% 25.67% 19.87% 24.12%
Net Working Capital to Revenue		 22.80% 19.65% 20.71% 23.28% 20.58% 22.31% 23.69% 24.42% 19.76% 14.02% 18.30%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.18 $0.63 $0.80 $0.89 $1.35 $0.69 $0.93 $0.93 $1.38 $0.79 $1.11
Adjusted Weighted Average Basic Shares Outstanding		 217.01M 241.85M 242.57M 242.93M 242.58M 243.11M 243.40M 243.45M 243.37M 242.77M 236.30M
Adjusted Diluted Earnings per Share		 $1.17 $0.63 $0.80 $0.89 $1.33 $0.69 $0.93 $0.93 $1.37 $0.79 $1.11
Adjusted Weighted Average Diluted Shares Outstanding		 218.18M 243.02M 243.54M 243.75M 243.52M 243.78M 243.86M 244.09M 243.99M 243.36M 236.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 241.77M 242.45M 242.89M 242.94M 243.05M 243.35M 243.41M 243.47M 243.14M 237.69M 233.49M
Normalized Net Operating Profit after Tax (NOPAT)		 161 171 217 229 254 194 248 272 349 213 288
Normalized NOPAT Margin		 7.60% 8.41% 9.99% 10.89% 11.25% 9.37% 10.78% 11.98% 14.57% 10.02% 12.31%
Pre Tax Income Margin		 9.92% 9.64% 11.39% 12.79% 16.62% 10.49% 12.99% 13.10% 15.35% 11.48% 15.58%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 16.00 15.00 23.45 27.90 25.78 28.13 34.22 50.50 62.33 62.00 53.00
NOPAT to Interest Expense		 19.09 11.65 18.06 22.59 25.79 22.22 25.39 42.36 53.24 47.25 39.95
EBIT Less CapEx to Interest Expense		 9.21 9.79 17.00 20.50 14.78 19.88 23.33 39.00 48.83 39.75 41.71
NOPAT Less CapEx to Interest Expense		 12.30 6.44 11.61 15.19 14.79 13.97 14.50 30.86 39.74 25.00 28.66
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 49.10% 49.32% 43.79% 41.33% 39.33% 39.82% 39.72% 40.30% 41.16% 41.05% 39.84%
Augmented Payout Ratio		 53.20% 54.15% 48.24% 45.42% 41.57% 41.81% 41.33% 41.89% 42.74% 99.18% 163.23%

Financials Breakdown Chart

Key Financial Trends

Xylem’s recent financial statements show improving profitability and a stronger cash position, but the company is also using significant debt and cash to fund share repurchases. The latest Q2 2026 results point to better operating execution than the comparable periods in 2025 and 2024, although investors should monitor leverage, working capital, and the company’s large goodwill balance.

  • Revenue growth has remained positive. Q2 2026 revenue increased to $2.34 billion from $2.30 billion in Q2 2025 and $2.17 billion in Q2 2024. Revenue has also generally trended higher since 2023, although the pace of growth has moderated from the sharp increases seen after the company’s expansion.
  • Profit margins improved meaningfully. Q2 2026 gross margin was approximately 41.2%, compared with 38.8% in Q2 2025 and 37.8% in Q2 2024. Operating margin rose to approximately 16.7%, versus 13.3% and 11.7% in those respective periods.
  • Net income and earnings per share are moving higher. Q2 2026 net income attributable to common shareholders was $263 million, or $1.11 per diluted share, compared with $226 million, or $0.93 per share, in Q2 2025. Q1 2026 diluted EPS was also $0.79, up from $0.69 in Q1 2025.
  • Operating cash flow has strengthened. Net cash from continuing operating activities was $553 million in Q2 2026, compared with $305 million in Q2 2025 and $288 million in Q2 2024. This provides support for capital investments, dividends, debt service, and shareholder returns.
  • Cash and liquidity improved during the first half of 2026. Cash and equivalents increased from $808 million at the end of Q1 2026 to $1.28 billion at the end of Q2. Total current assets of $4.39 billion exceeded current liabilities of $2.72 billion, implying a current ratio of roughly 1.6.
  • Share repurchases are reducing the share count. Xylem reported $680 million of common stock repurchases in Q2 2026 and $563 million in Q1. Weighted-average diluted shares declined to approximately 236.6 million in Q2 2026 from 244.0 million in Q4 2025, supporting per-share earnings growth.
  • Capital spending remains consistent and appears manageable. Purchases of property, plant and equipment were $89 million in Q2 2026 and $90 million in Q1, broadly similar to recent quarters. This spending supports the business but remains a recurring use of operating cash.
  • Working capital remains a cash-flow swing factor. Changes in operating assets and liabilities reduced continuing operating cash flow by $131 million in Q2 2026 and $253 million in Q1. Accounts receivable stood at $1.88 billion and inventories at $1.02 billion, requiring continued attention to collections and inventory management.
  • Debt increased sharply during Q2. Xylem issued $990 million of debt in Q2 2026 while repurchasing stock and paying dividends. Total short- and long-term debt rose to approximately $2.93 billion at quarter-end, up from $1.94 billion at the end of Q1. The additional borrowing helped boost cash, but it increases financial risk and future interest obligations.
  • The balance sheet carries substantial acquisition-related intangible assets. Goodwill was $8.26 billion and intangible assets were $2.15 billion at Q2 2026, together representing roughly 60% of total assets. Impairment charges have appeared in every reported income statement in the data, including $11 million in Q2 2026, so future write-downs remain a risk.

Overall, Xylem’s operating trend is favorable: revenue is growing, margins are expanding, earnings per share are benefiting from buybacks, and operating cash generation has improved. However, the latest quarter’s debt issuance and aggressive repurchase activity mean investors should evaluate whether the pace of buybacks is sustainable without relying on additional borrowing.

Several cash-flow figures are presented on a calculated or continuing-operations basis and may not be directly comparable with quarterly income-statement figures. The 2024 and 2025 periods also include restated data, so investors should consult Xylem’s filings when building a precise historical model.

09/08/26 05:27 PM ETAI Generated. May Contain Errors.

Xylem Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Xylem's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Xylem's net income appears to be on an upward trend, with a most recent value of $950 million in 2025, rising from $340 million in 2015. The previous period was $890 million in 2024. See Xylem's forecast for analyst expectations on what's next for the company.

Xylem's total operating income in 2025 was $1.22 billion, based on the following breakdown:
  • Total Gross Profit: $3.48 billion
  • Total Operating Expenses: $2.25 billion

Over the last 10 years, Xylem's total revenue changed from $3.65 billion in 2015 to $9.04 billion in 2025, a change of 147.3%.

Xylem's total liabilities were at $5.89 billion at the end of 2025, a 4.9% increase from 2024, and a 128.7% increase since 2015.

In the past 10 years, Xylem's cash and equivalents has ranged from $296 million in 2018 to $1.88 billion in 2020, and is currently $1.48 billion as of their latest financial filing in 2025.

Over the last 10 years, Xylem's book value per share changed from 11.62 in 2015 to 47.15 in 2025, a change of 305.8%.


Related Companies

Financial statements for NYSE:XYL last updated on 7/28/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Moderna’s 177% Surge Puts Cancer Biotech Back in Focus
Moderna shares surged 177% in a single trading session on August 19, adding about $45 billion in market value ...
The Tomorrow Investor | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...
Freedom Financial | Sponsoredtc pixel
What Is A Roth Conversion, And How Do I Set One Up?
A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...
SmartAsset | Sponsoredtc pixel
Musk just exposed the crack in his empire
SpaceX's IPO raised approximately $85.7 billion in gross proceeds. Days later, the company revealed its combin...
The Oxford Club | Sponsoredtc pixel
BlackRock and Vanguard already own THIS
Institutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...
Monument Traders Alliance | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel